{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:08:41Z","timestamp":1760299721137,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10147-017-1202-2","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T08:27:39Z","timestamp":1508833659000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics"],"prefix":"10.1007","volume":"23","author":[{"given":"Manaka","family":"Muneishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Suemitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6001-746X","authenticated-orcid":false,"given":"Yoshihiro","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","volume":"82","author":"F Lo Coco","year":"1993","unstructured":"Lo Coco F, Gaidano G, Louie DC et al (1993) P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289\u20132295","journal-title":"Blood"},{"key":"1202_CR2","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V91.12.4677","volume":"91","author":"KS Elenitoba-Johnson","year":"1998","unstructured":"Elenitoba-Johnson KS, Gascoyne RD, Lim MS et al (1998) Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677\u20134685","journal-title":"Blood"},{"key":"1202_CR3","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984","volume":"91","author":"M Pinyol","year":"1998","unstructured":"Pinyol M, Cobo F, Bea S et al (1998) P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin\u2019s lymphomas. Blood 91:2977\u20132984","journal-title":"Blood"},{"key":"1202_CR4","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1073\/pnas.132253599","volume":"99","author":"IS Lossos","year":"2002","unstructured":"Lossos IS, Alizadeh AA, Diehn M et al (2002) Transformation of follicular lymphoma to diffuse large-cell lym-phoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 99:8886\u20138891","journal-title":"Proc Natl Acad Sci USA"},{"key":"1202_CR5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2002-08-2482","volume":"102","author":"T Akasaka","year":"2003","unstructured":"Akasaka T, Lossos IS, Levy R (2003) BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 102:1443\u20131448","journal-title":"Blood"},{"key":"1202_CR6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2013-07-512392","volume":"123","author":"M Brodtkorb","year":"2014","unstructured":"Brodtkorb M, Lingjaerde OC, Huse K et al (2014) Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood 123:1051\u20131054","journal-title":"Blood"},{"key":"1202_CR7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"M Vasishtha","year":"2014","unstructured":"Vasishtha M, Messina M, Holmes AB et al (2014) Genetics of follicular lymphoma transformation. Cell Rep 6:130\u2013140","journal-title":"Cell Rep"},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3978\/j.issn.2304-3865.2015.01.01","volume":"4","author":"B Bai","year":"2015","unstructured":"Bai B, Huang HQ (2015) Individualized management of follicular lymphoma. Chin Clin Oncol 4:7. doi: 10.3978\/j.issn.2304-3865.2015.01.01","journal-title":"Chin Clin Oncol"},{"key":"1202_CR9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3960\/jslrt.54.31","volume":"54","author":"K Izutsu","year":"2014","unstructured":"Izutsu K (2014) Treatment of follicular lymphoma. J Clin Exp Hematop 54:31\u201337","journal-title":"J Clin Exp Hematop"},{"key":"1202_CR10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","volume":"28","author":"W Hiddemann","year":"2014","unstructured":"Hiddemann W, Cheson BD (2014) How we manage follicular lymphoma. Leukemia 28:1388\u20131395","journal-title":"Leukemia"},{"key":"1202_CR11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/PPO.0b013e31826aed6d","volume":"18","author":"VP Kenkre","year":"2012","unstructured":"Kenkre VP, Kahl BS (2012) What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma? Cancer J 18:383\u2013389","journal-title":"Cancer J"},{"key":"1202_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/107327481201900303","volume":"19","author":"C Bello","year":"2012","unstructured":"Bello C, Zhang L, Naghashpour M (2012) Follicular lymphoma: current management and future directions. Cancer Control 19:187\u2013195","journal-title":"Cancer Control"},{"key":"1202_CR13","doi-asserted-by":"crossref","unstructured":"Salles G, Ghesqui\u00e8res H, Bachy E (2012). What is the best first-line treatment strategy for patients with indolent lymphomas? Am Soc Clin Oncol Educ Book, pp 488\u2013493","DOI":"10.14694\/EdBook_AM.2012.32.37"},{"issue":"Suppl 1","key":"1202_CR14","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.clml.2011.04.006","volume":"11","author":"P McLaughlin","year":"2011","unstructured":"McLaughlin P (2011) Management options for follicular lymphoma: observe; R-CHOP; B-R; others? Clin Lymphoma Myeloma Leuk 11(Suppl 1):S91\u2013S95. doi: 10.1016\/j.clml.2011.04.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1202_CR15","first-page":"1422","volume":"90","author":"M Agthoven van","year":"2005","unstructured":"van Agthoven M, Kramer MH, Sonneveld P et al (2005) Cost analysis of common treatment options for indolent follicular non-Hodgkin\u2019s lymphoma. Haematologica 90:1422\u20131432","journal-title":"Haematologica"},{"key":"1202_CR16","first-page":"258","volume":"29","author":"S Schmitz","year":"2006","unstructured":"Schmitz S, Aly F, Steinmetz T et al (2006) Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma. Onkologie 29:258\u2013264","journal-title":"Onkologie"},{"key":"1202_CR17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinthera.2012.02.019","volume":"34","author":"EJ Soini","year":"2012","unstructured":"Soini EJ, Martikainen JA, Vihervaara V et al (2012) Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 34:915\u2013925","journal-title":"Clin Ther"},{"key":"1202_CR18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/erp.12.57","volume":"12","author":"KM Johnston","year":"2012","unstructured":"Johnston KM, Bolbocean C, Connors J et al (2012) Cost-effectiveness of rituximab in follicular lymphoma. Expert Rev Pharmacoecon Outcomes Res 12:569\u2013577","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1202_CR19","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","volume":"121","author":"A Prica","year":"2015","unstructured":"Prica A, Chan K, Cheung M (2015) Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis. Cancer 121:2637\u20132645","journal-title":"Cancer"},{"key":"1202_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MLR.0000000000000486","volume":"54","author":"MD Danese","year":"2016","unstructured":"Danese MD, Reyes CM, Gleeson ML et al (2016) Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care 54:343\u2013349","journal-title":"Med Care"},{"key":"1202_CR21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265","journal-title":"Blood"},{"key":"1202_CR22","first-page":"497","volume":"17","author":"N Milanovic","year":"2012","unstructured":"Milanovic N, Matkovic S, Ristic D et al (2012) Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. J BUON 17:497\u2013501","journal-title":"J BUON"},{"key":"1202_CR23","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","volume":"32","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Hong F, Williams ME et al (2014) Rituximab extended schedule or re-treatment trial for low tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol 32:3096\u20133102","journal-title":"J Clin Oncol"},{"key":"1202_CR24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/hon.2033","volume":"31","author":"AR Palla","year":"2013","unstructured":"Palla AR, Hamadani M (2013) Rituximab maintenance versus retreatment in follicular lymphoma. Hematol Oncol 31:171\u2013178","journal-title":"Hematol Oncol"},{"key":"1202_CR25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/10428190903503404","volume":"51","author":"A Johnston","year":"2009","unstructured":"Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F et al (2009) Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymph 51:399\u2013405","journal-title":"Leuk Lymph"},{"key":"1202_CR26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"1202_CR27","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u20132952","journal-title":"Blood"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1202-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1202-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1202-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T10:33:14Z","timestamp":1603189994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1202-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1202-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}